Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

197.42USD
17 Aug 2018
Change (% chg)

$0.98 (+0.50%)
Prev Close
$196.44
Open
$196.24
Day's High
$198.51
Day's Low
$195.28
Volume
2,183,845
Avg. Vol
2,890,719
52-wk High
$201.23
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $127,784.50
Shares Outstanding(Mil.): 647.27
Dividend: 1.32
Yield (%): 2.67

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.43 28.29 30.45
EPS (TTM): 12.02 -- --
ROI: 13.20 12.92 12.63
ROE: 36.30 14.94 14.82

UPDATE 3-Teva Pharm shares sink as sales forecast disappoints market

* Company still sees FDA approval of migraine drug mid-September

Aug 02 2018

Amgen profit beats Street view, will not raise prices again in 2018

Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

Jul 26 2018

UPDATE 2-Amgen profit beats Street view, will not raise prices again in 2018

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

Jul 26 2018

Amgen CEO says will not raise drug prices again this year

Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

Jul 26 2018

Amgen CEO says will not raise drug prices again this year

July 26 Amgen Inc Chief Executive Robert Bradway said on Thursday that the biotechnology company will not raise drug prices for the remainder of the year.

Jul 26 2018

Amgen quarterly profit beats Wall Street view on new product sales

July 26 Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year forecast, as growth of newer drugs like cholesterol fighter Repatha and osteoporosis drug Prolia offset weakness in older products.

Jul 26 2018

RPT-FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

Jul 26 2018

Amgen's new migraine drug hits insurance hurdles

Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

Jul 26 2018

FOCUS-Amgen's new migraine drug hits insurance hurdles

July 26 Amgen Inc's push to get patients on its new $575 a month migraine drug before competition emerges in September is facing barriers from insurers.

Jul 26 2018

BRIEF-Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™

* AMGEN AND NOVARTIS PRESENT NEW DATA DEMONSTRATING LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF AIMOVIG™ (ERENUMAB-AOOE) IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE

Jun 28 2018

Earnings vs. Estimates